MISGAV, Israel & LONDON--(BUSINESS WIRE)--Medgenics (AIM:MEDG), the US-incorporated biopharmaceutical company developing the ‘Biopump’ sustained-action protein therapy for the treatment of chronic diseases, is pleased to announce its first full year results since the admission of the Company’s shares to trading on AIM. The Annual Report and Accounts of the Company and its subsidiary (the Group) for the year ended 31 December 2007 will be posted to shareholders during the week commencing 23 June 2008 and will be available on the Company’s website (www.medgenics.com).
